Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

PET in lymphoma: who, when, how often, pitfalls?

verfasst von: MD Christian Uprimny

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

For optimal therapy management in patients with lymphoma, sensitive and specific imaging modalities for accurate initial staging and evaluation of response to therapy are crucial. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) that combines metabolic information of 18F-FDG PET with morphological information of diagnostic CT has proven to be a very useful tool in the work-up of lymphomas. Especially in 18F-FDG-avid tumours like Hodgkin lymphoma and high-grade, aggressive non-Hodgkin lymphoma, 18F-FDG PET/CT is widely used for pre-treatment staging and response evaluation after completion of therapy with convincing evidence that it is more accurate than conventional imaging modalities. Although 18F-FDG PET/CT is also applied in other subtypes of lymphoma and in other clinical indications such as early response assessment, its benefit in these settings remains controversial. This review is intended to highlight the accepted clinical applications for 18F-FDG PET/CT in lymphoma, delivering a short clinical guideline when it is recommended to perform 18F-FDG PET/CT in a patient with lymphoma.
Literatur
1.
Zurück zum Zitat Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8. PubMed Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8. PubMed
2.
Zurück zum Zitat Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkinʼs lymphoma. Haematologica. 2006;91:482–9. PubMed Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkinʼs lymphoma. Haematologica. 2006;91:482–9. PubMed
3.
Zurück zum Zitat Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology. 2004;232:823–9. CrossRefPubMed Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology. 2004;232:823–9. CrossRefPubMed
4.
Zurück zum Zitat Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(3):620–5. CrossRefPubMedCentralPubMed Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(3):620–5. CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. CrossRefPubMed Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. CrossRefPubMed
6.
Zurück zum Zitat Pelosi E, Pregno P, Penna D, et al. Role of whole body [18F] fluorodeoxyglucose positron emission tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med. 2008;113(4):578–90. CrossRefPubMed Pelosi E, Pregno P, Penna D, et al. Role of whole body [18F] fluorodeoxyglucose positron emission tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med. 2008;113(4):578–90. CrossRefPubMed
7.
Zurück zum Zitat Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of (18F)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14. CrossRefPubMed Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of (18F)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14. CrossRefPubMed
8.
Zurück zum Zitat Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkinʼs lymphoma (NHL). Ann Oncol. 2001;12(6):825–30. CrossRefPubMed Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkinʼs lymphoma (NHL). Ann Oncol. 2001;12(6):825–30. CrossRefPubMed
9.
Zurück zum Zitat Bishu S, Quigley J.M., Schmitz J, et al. F-18-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48(8):1531–8. CrossRefPubMed Bishu S, Quigley J.M., Schmitz J, et al. F-18-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48(8):1531–8. CrossRefPubMed
10.
Zurück zum Zitat Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685–90. CrossRefPubMed Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685–90. CrossRefPubMed
11.
Zurück zum Zitat Hofmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10(10):1185–9. CrossRef Hofmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10(10):1185–9. CrossRef
12.
Zurück zum Zitat Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30. CrossRefPubMed Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30. CrossRefPubMed
13.
Zurück zum Zitat Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluouro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066–74. CrossRefPubMed Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluouro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066–74. CrossRefPubMed
14.
Zurück zum Zitat Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16(5):337–45. CrossRefPubMed Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16(5):337–45. CrossRefPubMed
15.
Zurück zum Zitat Schoeder H, Meta J, Yap C, et al. Effect of whole body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8):1139–43. Schoeder H, Meta J, Yap C, et al. Effect of whole body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8):1139–43.
16.
Zurück zum Zitat Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(9):620–5. CrossRefPubMedCentralPubMed Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(9):620–5. CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Cheng G, Chen W, Chamroonraat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011;38(8):1469–76. CrossRefPubMed Cheng G, Chen W, Chamroonraat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011;38(8):1469–76. CrossRefPubMed
18.
Zurück zum Zitat Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60–7. CrossRefPubMed Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60–7. CrossRefPubMed
19.
Zurück zum Zitat El-Galaly TC, dʼAmore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14. CrossRefPubMed El-Galaly TC, dʼAmore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14. CrossRefPubMed
20.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Aug 11. Epub ahead of print. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Aug 11. Epub ahead of print.
21.
Zurück zum Zitat Von Treskow B, Plütschow A, Fuchs A, et al. Dose-intensification in early unfavorable Hodgkinʼs lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13. CrossRef Von Treskow B, Plütschow A, Fuchs A, et al. Dose-intensification in early unfavorable Hodgkinʼs lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13. CrossRef
22.
Zurück zum Zitat Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(Suppl. 1):28–33. CrossRefPubMed Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(Suppl. 1):28–33. CrossRefPubMed
23.
Zurück zum Zitat Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkinʼs lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906–14. CrossRefPubMed Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkinʼs lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906–14. CrossRefPubMed
24.
Zurück zum Zitat Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkinʼs disease. Haematologica. 2006;91(4):475–81. PubMed Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkinʼs disease. Haematologica. 2006;91(4):475–81. PubMed
25.
Zurück zum Zitat Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43. CrossRefPubMed Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43. CrossRefPubMed
26.
Zurück zum Zitat Moskowitz AJ, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–7. CrossRefPubMedCentralPubMed Moskowitz AJ, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–7. CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8. CrossRefPubMed Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8. CrossRefPubMed
28.
Zurück zum Zitat Juweid ME. 18F-FDG PET as a routine test for post therapy assessment of Hodgkinʼs lymphoma: where is the evidence. J Nucl Med. 2008;49(1):9–12. CrossRefPubMed Juweid ME. 18F-FDG PET as a routine test for post therapy assessment of Hodgkinʼs lymphoma: where is the evidence. J Nucl Med. 2008;49(1):9–12. CrossRefPubMed
29.
Zurück zum Zitat Zijlstra JM, Linduer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systemic review. Haematologica. 2006;91(4):522–9. PubMed Zijlstra JM, Linduer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systemic review. Haematologica. 2006;91(4):522–9. PubMed
30.
Zurück zum Zitat Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma. Br J Haematol. 2001;115(4):793–800. CrossRefPubMed Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma. Br J Haematol. 2001;115(4):793–800. CrossRefPubMed
31.
Zurück zum Zitat Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781–7. CrossRefPubMed Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781–7. CrossRefPubMed
32.
Zurück zum Zitat Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with lymphoma. Ann Hematol. 2009;88(12):1229–36. CrossRefPubMed Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with lymphoma. Ann Hematol. 2009;88(12):1229–36. CrossRefPubMed
Metadaten
Titel
PET in lymphoma: who, when, how often, pitfalls?
verfasst von
MD Christian Uprimny
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0175-3

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe